Dariohealth reports fourth quarter and record revenue in full-year 2022 financial and operating results

Continued to improve the financial profile of the company full-year 2022 revenue of $27.7 million increased 34.8% over $20.5 million in 2021, as b2b revenue growth more than offset managed reduction of b2c activities commercial revenue contributed 59% to 2022 full-year total revenue, compared to 4% for the full-year 2021 gross margin was 40.1% of revenues for the fourth quarter of 2022, up from 9.1% of revenues for the fourth quarter of 2021 pro-forma gross margin was 58% of revenues for the fourth quarter of 2022, up from 22% of revenues for the fourth quarter of 2021 58.4% reduction in operating loss in the fourth quarter 2022 as compared to the fourth quarter of 2021 sequential 38.2% reduction in operating loss from the third quarter to fourth quarter of 2022 ended 2022 with cash and cash equivalents of $49.3 million company to host investor conference call and webcast at 8:30 a.m. et today new york , march 9, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital therapeutics (dtx) market, today reported financial results for the fourth quarter and full year 2022 and provided a corporate and commercial update.
DRIO Ratings Summary
DRIO Quant Ranking